reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

GPCR Events, Meetings, and Webinars NEW AACR 2023 - American Association for Cancer Research (April 14

Therapeutics and Chime Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer

protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer

kidney disease GPCRs in Oncology and Immunology Purinergic GPCR-integrin interactions drive pancreatic cancer

Berndt, Ines Liebscher, and Susanne Horn et. al for their for their research on adhesion GPCR transcript variants February 26th to March 3rd, 2024 Adhesion GPCRs The repertoire and structure of adhesion GPCR transcript variants endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic target in cancer

and Immunology [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer

News Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer

Reviews, GPCRs, and more Lessons from the physiological role of guanosine in neurodegeneration and cancer

fibroblast heterogeneity in fibroblast-associated diseases Ultrasensitive dose-response for asbestos cancer

4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer

mutational scanning (DMS) is a powerful method for studying the functional consequences of various genetic variants significant challenge in drug development, particularly in the treatment of infectious diseases and cancer DMS aids in the advent of precision medicine by enabling a more detailed understanding of how genetic variation This could expand the method's capability to explore larger genomic regions and more intricate genetic variations Measuring the activity of protein variants on a large scale using deep mutational scanning.

Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer

Microbiota Effects on the Immune System, and Western Diseases Lactate receptor GPR81 drives breast cancer

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

GPCRs in Oncology and Immunology GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer

in a mouse model of sciatic nerve injury GPCRs in Oncology and Immunology GPR37 promotes colorectal cancer

infection Industry News InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer

Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers

Small-molecule targeting of GPCR-independent non-canonical G protein signaling inhibits cancer progression

macrophage migration during tissue inflammation From odor to oncology: non-canonical odorant receptors in cancer

and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer

founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer

Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling

Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer

for a number of inflammatory diseases including atherosclerosis, scleroderma, multiple sclerosis and cancer and efficiently advance a diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer